📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-07-29 21:15
570 analysed today
570
Today
133,459
All-time analysed
40,112
Positive
6,281
Negative
79,251
Neutral
7,747
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
31 announcements match the current filters (relevance ≥ 5).
Syngene Q1 FY27: Revenue down 16% to ₹736 Cr; PAT drops to ₹1 Cr on lower client offtake
Syngene reported a weak Q1 FY27 with revenue declining 16% YoY to ₹736 Cr, primarily due to reduced demand from a major Large Molecule CDMO client. Operating EBITDA margins halved to 12.3% from 23.6% a year ago, further pressured by a ₹50 Cr forex hedge loss. Consequently, PAT (before exceptional items) plummeted 99% to just ₹1 Cr. Management expects a recovery in H2 FY27, guiding for single-digit revenue degrowth and mid-20s EBITDA margins for the full year.
Confidence: HIGH
What changedSyngene experienced a sharp decline in quarterly profitability and revenue due to specific client offtake issues and significant forex losses, alongside a leadership transition.
Why it mattersThe results highlight the impact of client concentration (top two clients contribute 41% of revenue) and the current volatility in the global biologics manufacturing demand.
Revenue (Q1 FY27): ₹736 CrYoY Revenue Growth: -16%Operating EBITDA Margin: 12.3%Forex Loss: ₹50 CrPAT (Before Exceptional): ₹1 CrRevenue vs TTM Revenue: ~20.6%
📅 Short termNegative sentiment is expected in the short term due to the massive PAT drop and margin compression, which significantly missed historical averages.
📈 Long termStructural growth remains tied to the 'China switcher' strategy and expansion in Large Molecule CDMO (Baltimore/Stelis facilities), but recovery is back-ended to H2 FY27.
⚠ Risk flags
- High client concentration (top 2 clients are 41% of revenue)
- Forex volatility impacting margins
- Execution risks at the new Baltimore facility
Key Highlights
Revenue from operations fell 16% YoY to ₹736 Cr for the quarter ended June 30, 2026
Operating EBITDA margin contracted sharply to 12.3% from 23.6% in the previous year
PAT (before exceptional items) stood at ₹1 Cr, a 99% decline from ₹87 Cr in Q1 FY26
Foreign exchange hedge loss increased significantly to ₹50 Cr compared to ₹5 Cr in the same quarter last year
Management transition completed with Siddharth Mittal assuming the MD & CEO role on July 1, 2026
👀 What to Watch
Monitor the recovery in Large Molecule CDMO offtake and the operationalization of the Baltimore facility by Dec 2025. Investors should watch if the company can achieve its guided mid-20s EBITDA margins in H2 FY27 to offset the weak start.
Q1 FY27 Revenue down 16% to ₹736 Cr; EBITDA Margin contracts to 12%
Syngene reported a weak Q1 FY27 with revenue declining 16% YoY to ₹736 Cr and Operating EBITDA falling 56% to ₹91 Cr. The EBITDA margin halved to 12% from 24% in the previous year, primarily due to reduced offtake from a major biologics client and forex hedge losses. Management has guided for continued degrowth in H1 FY27 but expects a recovery in H2, targeting mid-20s EBITDA margins for the full year. Kiran Mazumdar-Shaw has assumed the role of Executive Chairperson to lead a strategic repositioning focused on CDMO and AI-led services.
Confidence: HIGH
What changedSyngene experienced a sharp decline in quarterly profitability and revenue, leading to a leadership reshuffle and a downward revision of near-term growth expectations.
Why it mattersThe results highlight the company's vulnerability to client concentration (top two clients account for 41% of revenue) and the current volatility in global biotech funding and demand.
Q1 FY27 Revenue: ₹736 CrQ1 FY27 EBITDA Margin: 12%YoY Revenue Growth: -16%YoY EBITDA Growth: -56%Q1 Revenue vs TTM Revenue: 20.6%Exceptional Item (Net of Tax): ₹10 Cr
📅 Short termThe stock is likely to face pressure in the short term due to the significant earnings miss and the guidance of continued degrowth in the first half of the fiscal year.
📈 Long termThe long-term outlook depends on the successful ramp-up of the CDMO business and the US manufacturing facility, alongside the strategic shift toward AI-led drug discovery.
⚠ Risk flags
- High client concentration
- Forex hedge losses
- Execution risk in US facility operationalization
- Subdued biotech funding environment
Key Highlights
Revenue from operations declined 16% YoY to ₹736 Cr, representing ~20.6% of TTM revenue.
Operating EBITDA fell 56% YoY to ₹91 Cr, with margins compressing by 1,200 bps to 12%.
Reported a net loss of ₹9 Cr after an exceptional item of ₹10 Cr related to employee termination benefits.
Management expects single-digit revenue degrowth for the full year FY27 with EBITDA margins in the mid-20s.
Board restructured with Kiran Mazumdar-Shaw as Executive Chairperson and appointment of two new Independent Directors from deep-tech and pharma backgrounds.
👀 What to Watch
Investors should monitor the recovery trajectory in H2 FY27 and the operationalization of the Baltimore, USA facility by December 2025. Key metrics to watch include the stabilization of demand from major biologics clients and the execution of the 'China switcher' strategy.
Syngene Q1 FY27: Revenue drops 24% YoY to ₹663 Cr; reports net loss of ₹2.1 Cr
Syngene International reported a weak Q1 FY27 with consolidated revenue from operations falling 24.2% YoY to ₹663 crore. The company swung to a net loss of ₹2.1 crore, compared to a profit of ₹86.7 crore in the same quarter last year, impacted by a ₹13.5 crore exceptional loss and a sharp rise in foreign exchange losses to ₹48 crore. Operational performance was pressured by high employee costs (₹207 crore) relative to the lower revenue base, reflecting ongoing headwinds in the global biotech R&D spending environment.
Confidence: HIGH
What changedSyngene has transitioned from a profitable entity to reporting a net loss on a consolidated basis, accompanied by a significant double-digit revenue contraction.
Why it mattersThe results indicate that the inventory corrections and subdued biotech funding mentioned in previous filings are having a deeper-than-expected impact on the company's financial health and margins.
Revenue from Operations (Q1 FY27): ₹663.0 crNet Profit/Loss (Q1 FY27): -₹2.1 crYoY Revenue Growth: -24.2%Exceptional Loss: ₹13.5 crForeign Exchange Loss: ₹48.0 crQuarterly Revenue vs TTM Revenue: 18.5%
📅 Short termThe stock is likely to face downward pressure in the coming weeks as the market reacts to the unexpected loss and the sharp decline in revenue compared to historical quarterly averages.
📈 Long termLong-term recovery depends on the successful ramp-up of the 50,000L biologics capacity and the company's ability to diversify its client base beyond the top two customers who currently contribute 41% of revenue.
⚠ Risk flags
- High client concentration
- Foreign exchange volatility
- Continued weakness in global biotech R&D funding
- Liquidation of subsidiary Syngene Manufacturing Solutions Limited
Key Highlights
Consolidated revenue from operations declined to ₹663 crore from ₹874.5 crore in the year-ago period.
Reported a consolidated net loss of ₹2.1 crore against a profit of ₹86.7 crore in Q1 FY26.
Exceptional items resulted in a net loss of ₹13.5 crore during the quarter.
Foreign exchange fluctuation loss surged to ₹48 crore compared to ₹4.8 crore in the previous year's quarter.
Employee benefit expenses remained high at ₹207 crore, accounting for 31.2% of quarterly revenue.
👀 What to Watch
Investors should monitor management's guidance on the recovery of US biotech funding and the specific timeline for the Baltimore facility becoming operational by December 2025. Watch for any updates on the 'China switcher' strategy to offset current revenue contraction.
Syngene CEO Peter Bains Steps Down Effective June 30, 2026
Mr. Peter Bains has officially resigned as Managing Director and CEO of Syngene International, effective from the close of business on June 30, 2026. This follows a prior notification to the exchanges on March 27, 2026, regarding a planned leadership succession. The transition occurs as the company targets a 20% growth rate and works toward operationalizing its Baltimore, USA facility by December 2025. Given the company's high client concentration, where the top two customers account for 41% of FY25 revenue, leadership stability is critical for maintaining long-term service contracts.
Confidence: HIGH
What changedThe formal resignation and exit of the Managing Director & CEO following a pre-announced transition period.
Why it mattersA change in top leadership is significant for a CRO/CDMO business that relies heavily on long-term client relationships and complex global expansion projects like the Baltimore facility.
Effective Resignation Date: June 30, 2026TTM Revenue: ₹3,575 CrTop 2 Client Concentration: 41%Target Growth Rate: 20%
📅 Short termThe market is likely to remain neutral as the resignation was previously disclosed in March 2026; focus will be on the immediate handover process.
📈 Long termThe long-term impact depends on the new leadership's ability to navigate subdued US biotech funding and successfully scale the Large Molecule CDMO business.
⚠ Risk flags
- Leadership transition risk
- High client concentration
- Execution risk for US facility
Key Highlights
Resignation of Mr. Peter Bains as MD & CEO effective June 30, 2026
Initial intimation of the leadership transition was made on March 27, 2026
Company reported TTM revenue of ₹3,575 Cr and a PAT of ₹317 Cr
Top two customers contribute 41% of FY25 revenues, necessitating smooth client handovers
Baltimore facility expansion remains on track for operationalization by December 2025
👀 What to Watch
Investors should monitor the formal appointment and strategic priorities of the successor, particularly regarding the execution of the '1-3-5' growth plan and the integration of the Baltimore facility.
Syngene sets July 29 for AGM; proposes ₹1.25 dividend and ₹25 Cr CEO compensation
Syngene International has scheduled its 33rd Annual General Meeting (AGM) for July 29, 2026. The board has recommended a final dividend of ₹1.25 per share for FY26. A major agenda item is the formal appointment of Siddharth Mittal as MD & CEO for a 5-year term with a total annual compensation package of ₹25 Cr, representing approximately 7.9% of the company's TTM PAT of ₹317 Cr. Additionally, the company is seeking shareholder approval for director remuneration in years with inadequate profits and the appointment of new statutory auditors.
Confidence: HIGH
What changedThe company has formalized the leadership transition and compensation structure for the MD & CEO for the next five years, alongside routine dividend and auditor appointments.
Why it mattersLeadership continuity is critical as Syngene executes its '1-3-5 plan' and operationalizes its Baltimore facility by December 2025. The high CEO compensation relative to current PAT (7.9%) reflects the cost of top-tier management in the global CRO/CDMO space.
Proposed Final Dividend: ₹1.25 per shareCEO Total Compensation: ₹25 CrCEO Pay vs TTM PAT: ~7.89%Auditor Appointment Term: 5 yearsTTM PAT: ₹317 Cr
📅 Short termThe stock may see minor activity around the dividend record date; however, the AGM notice is largely procedural and expected.
📈 Long termThe 5-year mandate for the MD & CEO provides stability for long-term strategic initiatives like the 'China switcher' strategy and expansion in Large Molecule CDMO.
⚠ Risk flags
- High executive compensation relative to current net profit levels
- Special resolution for remuneration during inadequate profits suggests caution regarding near-term margin pressure
Key Highlights
Proposed final dividend of ₹1.25 per equity share for the financial year ended March 31, 2026.
MD & CEO Siddharth Mittal's total compensation fixed at ₹25 Cr, including ₹10 Cr fixed pay and ₹10 Cr long-term incentives.
Appointment of S. R. Batliboi & Associates LLP as Statutory Auditors for a 5-year term until the 38th AGM.
Special resolution proposed to pay managerial remuneration up to 15% of net profits, even in case of inadequate profits.
AGM to be conducted via Video Conferencing on July 29, 2026, at 3:30 PM IST.
👀 What to Watch
Investors should monitor the voting results on the special resolutions, particularly the executive compensation structure and the provision for remuneration during low-profit periods, given the recent volatility in earnings.
Siddharth Mittal Appointed as MD & CEO of Syngene International Effective July 1, 2026
Syngene International has appointed Siddharth Mittal as its new Managing Director and CEO, effective July 1, 2026, succeeding Peter Bains. Mittal transitions from parent company Biocon Limited, where he served as MD & CEO and previously as CFO for 13 years. This leadership change occurs as the company navigates a challenging period, including a 37% YoY PAT decline in Q2 FY26 due to inventory corrections and a slowdown in US biotech funding. The new CEO is tasked with restoring growth momentum and executing the company's '1-3-5 plan' to achieve a targeted 20% growth rate.
Confidence: HIGH
What changedA leadership transition at the MD & CEO level, moving from Peter Bains to Siddharth Mittal, who was previously the head of the parent company, Biocon.
Why it mattersThe CEO change is critical for Syngene as it attempts to pivot toward Large Molecule CDMO services and recover from recent revenue impact factors like inventory corrections and subdued discovery services demand.
Effective Date: July 01, 2026Total Employees: 8,300+Scientist Count: 5,700+Global Customers: ~400Facility Area: 3 Mn+ sq. ft
📅 Short termThe stock may see neutral to cautious movement as the market assesses the transition; immediate focus will be on the new CEO's execution discipline.
📈 Long termMittal's experience in global commercial operations and regulatory approvals at Biocon could be structurally positive for Syngene's international expansion and CDMO scaling.
⚠ Risk flags
- High client concentration (top two customers account for 41% of revenue)
- Execution risk during leadership transition
- External macro headwinds in US biotech funding
Key Highlights
Siddharth Mittal succeeds Peter Bains as MD & CEO effective July 1, 2026.
Mittal brings nearly 30 years of leadership experience, including a successful tenure commercializing Biocon's GLP-1 portfolio.
Syngene currently operates with over 8,300 employees and 5,700+ scientists across 3 million sq. ft of facilities.
The company serves approximately 400 global customers, including major players like BMS, GSK, and Merck KGaA.
Management transition occurs as the company aims to operationalize its Baltimore, USA facility by December 2025.
👀 What to Watch
Investors should monitor the next few quarterly earnings calls for shifts in strategic priorities and updates on the 'China switcher' strategy and the operationalization of the Baltimore facility.
Syngene Announces Rs 1.25 Final Dividend for FY26; Sets Record Date and TDS Guidelines
Syngene International has recommended a final dividend of Rs 1.25 per equity share (12.50% of face value) for the financial year ended March 31, 2026. The company has fixed June 26, 2026, as the record date to determine eligibility for the payout. Shareholders are required to submit relevant tax documents by July 10, 2026, to ensure appropriate Tax Deducted at Source (TDS) rates are applied. The dividend is subject to shareholder approval at the Annual General Meeting scheduled for July 29, 2026.
Key Highlights
Final dividend recommended at Rs 1.25 per equity share of Rs 10 face value (12.50%)
Record date for dividend eligibility is fixed as Friday, June 26, 2026
Standard TDS rate of 10% for resident shareholders with valid PAN and 20% for those without
Deadline for submitting tax exemption documents (Form 15G/15H/TRC) is July 10, 2026
Annual General Meeting for dividend approval is scheduled for July 29, 2026
👀 What to Watch
Shareholders should ensure their PAN and bank account details are updated with their Depository Participant and submit tax-related declarations by July 10 to avoid higher tax withholding.
Syngene Shareholders Approve Kiran Mazumdar-Shaw's Role Change to Executive Chairperson
Syngene International Limited has successfully passed a special resolution via postal ballot to transition Ms. Kiran Mazumdar-Shaw from Non-Executive Chairperson to Executive Chairperson. The resolution, which includes the approval of managerial remuneration, received 91.40% of the total valid votes in favor. Notably, while the promoter group was 100% in favor, approximately 21.57% of institutional investors voted against the proposal, indicating some level of shareholder concern regarding the change or remuneration terms.
Key Highlights
Special resolution passed to change Ms. Kiran Mazumdar-Shaw's role to Executive Chairperson and Key Managerial Personnel (KMP).
Total valid votes cast were 35,13,42,683, representing 87.19% of the total paid-up equity capital.
The resolution was approved with a 91.40% majority (32,11,29,387 votes in favor).
Institutional investors showed significant dissent, with 21.57% (3,02,04,762 votes) voting against the resolution.
The promoter group held 21,22,83,697 shares and voted 100% in favor of the resolution.
👀 What to Watch
Investors should note the transition of the founder to an executive role which ensures leadership continuity, but should also investigate the reasons behind the 21.57% institutional dissent regarding remuneration or governance.
Syngene Seeks Approval to Appoint Kiran Mazumdar-Shaw as Executive Chair with ₹4 Cr Annual Pay
Syngene International has initiated a postal ballot to transition Ms. Kiran Mazumdar-Shaw from Non-Executive to Executive Chairperson for a five-year term starting April 1, 2026. The proposed annual remuneration is capped at ₹4.00 Crores, which includes a monthly salary of ₹33.33 Lakhs and statutory contributions. Since Ms. Mazumdar-Shaw is over 70 years of age, the appointment requires approval via a Special Resolution. Shareholders can cast their votes through remote e-voting between May 21 and June 19, 2026.
Key Highlights
Proposed transition of Ms. Kiran Mazumdar-Shaw to Executive Chairperson for a 5-year term effective April 1, 2026.
Managerial remuneration fixed at a maximum of ₹4.00 Crores per annum, including PF and Gratuity.
Special Resolution required under Companies Act as the appointee has attained the age of 70 years.
Remote e-voting period is scheduled from May 21, 2026, to June 19, 2026, with results by June 23, 2026.
The appointee will be a Key Managerial Personnel (KMP) and will not be entitled to sitting fees for board meetings.
👀 What to Watch
Investors should support the resolution to ensure leadership continuity; the proposed remuneration is well within industry standards for a company of Syngene's market capitalization.
Syngene Q4 FY26: Revenue up 2% to ₹1,037 Cr; PAT declines 16% YoY
Syngene International reported a modest 3% YoY revenue growth for FY26, reaching ₹3,739 crore, while Q4 revenue grew 2% to ₹1,037 crore. Profitability faced significant pressure as Q4 PAT (before exceptional items) declined 16% YoY to ₹153 crore, and full-year PAT fell 20% to ₹380 crore. Operating EBITDA margins for the year contracted to 25% from 29% in FY25. The company also announced a major leadership transition with Siddharth Mittal appointed as MD & CEO effective July 2026.
Key Highlights
FY26 Revenue from operations stood at ₹3,739 Cr, a 3% increase YoY.
Q4 FY26 PAT before exceptional items fell 16% YoY to ₹153 Cr.
Full-year Operating EBITDA margin compressed to 25% compared to 29% in FY25.
Expanded ADC capabilities and acquired a biologics site in Baltimore, USA, bringing total bioreactor capacity to 50,000L.
Siddharth Mittal to succeed Peter Bains as MD & CEO effective July 1, 2026.
👀 What to Watch
The stock may face short-term pressure due to margin contraction and declining profits. Investors should focus on the execution of the new ADC platform and the integration of the US facility as drivers for future growth.
Syngene FY26 PAT Drops 36% to ₹3,167 Million; Recommends ₹1.25 Final Dividend
Syngene International reported a consolidated revenue of ₹37,387 million for FY26, representing a modest 2.6% growth year-on-year. However, Profit After Tax (PAT) declined significantly by 36% to ₹3,167 million, down from ₹4,962 million in the previous year, primarily due to higher employee expenses and exceptional losses. The board has recommended a final dividend of ₹1.25 per share with a record date of June 26, 2026. Additionally, the company has appointed S. R. Batliboi & Associates LLP as its new statutory auditors for a five-year term.
Key Highlights
Consolidated Revenue for FY26 grew 2.6% YoY to ₹37,387 million.
Consolidated PAT for FY26 fell 36% to ₹3,167 million from ₹4,962 million in FY25.
Recommended a final dividend of ₹1.25 per equity share of ₹10 face value.
Exceptional items resulted in a net loss of ₹766 million in FY26 versus a gain of ₹320 million in FY25.
Employee benefit expenses increased by 12.3% YoY to ₹11,049 million.
👀 What to Watch
Investors should exercise caution as the sharp decline in profitability and margin pressure outweigh the marginal revenue growth. Monitor management's outlook on cost rationalization and the nature of exceptional items before making new entries.
Syngene Announces CEO Succession: Siddharth Mittal to Replace Peter Bains from July 1, 2026
Syngene International has announced a planned leadership transition where Mr. Peter Bains will step down as Managing Director and CEO on June 30, 2026. Mr. Siddharth Mittal is scheduled to take over the MD and CEO role effective July 1, 2026. Consequently, the company has updated its list of Key Managerial Personnel (KMP) authorized to determine the materiality of events for stock exchange disclosures. This early announcement suggests a structured succession plan aimed at ensuring management stability.
Key Highlights
Mr. Peter Bains to step down as MD & CEO effective close of business on June 30, 2026.
Mr. Siddharth Mittal appointed as the new MD & CEO effective July 1, 2026.
Board approved amendments to the Policy on Determination of Materiality of Events on April 29, 2026.
CFO Deepak Jain and CS Chethan Yogesh remain in their current roles as authorized KMPs for disclosures.
👀 What to Watch
Investors should monitor for any strategic shifts following the leadership change in mid-2026, though the long lead time typically indicates a stable transition. No immediate portfolio action is required.
Syngene FY26 PAT Drops 36% to ₹3,167 Million; ₹1.25 Dividend Declared and New Auditor Appointed
Syngene International reported a challenging FY26 with consolidated net profit falling 36% to ₹3,167 million from ₹4,962 million in the previous year. While annual revenue saw a marginal growth of 2.6% to ₹37,387 million, profitability was severely impacted by higher employee costs and a net exceptional loss of ₹766 million. The board has recommended a final dividend of ₹1.25 per share and proposed S.R. Batliboi & Associates LLP as the new statutory auditors for a five-year term.
Key Highlights
Consolidated Revenue for FY26 stood at ₹37,387 million, up slightly from ₹36,424 million in FY25.
Full-year Consolidated Net Profit declined significantly to ₹3,167 million compared to ₹4,962 million in the prior year.
Board recommended a final dividend of ₹1.25 per equity share (12.5% of face value) for FY25-26.
Employee benefit expenses increased by 12.3% YoY to ₹11,049 million, impacting operating margins.
M/s S. R. Batliboi & Associates LLP appointed as Statutory Auditors for 5 years, subject to shareholder approval.
👀 What to Watch
Investors should exercise caution as the sharp decline in net profit and rising employee costs indicate margin pressure. Monitor the management's commentary on the exceptional losses and the outlook for revenue acceleration in the coming quarters.
Syngene Appoints Vijaya Chandru and Arun Chandavarkar to Board; Reappoints Vinita Bali
Syngene International has announced the appointment of two new Independent Non-Executive Directors, Mr. Vijaya Chandru and Mr. Arun Chandavarkar, for three-year terms effective from July 2026. Mr. Chandru brings specialized expertise in computational biology and AI, while Mr. Chandavarkar, a former CEO of Biocon, provides deep industry knowledge in biopharmaceuticals. Additionally, the company has extended the tenure of Ms. Vinita Bali as a Non-Executive Director for one year until July 2027. These moves are aimed at strengthening the board's technical and strategic leadership capabilities.
Key Highlights
Appointment of Mr. Vijaya Chandru (PhD from MIT) as Independent Director for a 3-year term until 2029.
Appointment of Mr. Arun Chandavarkar (former Biocon CEO) as Independent Director for a 3-year term until 2029.
Reappointment of Ms. Vinita Bali (former Britannia CEO) as Non-Executive Director for 1 year from July 2026.
All appointments are subject to shareholder approval at the 33rd AGM scheduled for July 29, 2026.
👀 What to Watch
Investors should view these high-profile appointments as a positive sign of Syngene's commitment to technical excellence and strong corporate governance. No immediate action is required as these changes are part of a planned board refreshment.
Syngene Q4 FY26 Revenue Up 2% to Rs 1,037 Cr; PAT Before Exceptional Items Down 16%
Syngene reported a modest 2% YoY revenue growth in Q4 FY26 to Rs 1,037 Cr, while full-year revenue grew 3% to Rs 3,739 Cr. Profitability faced significant pressure as Q4 PAT (before exceptional items) fell 16% YoY to Rs 153 Cr, and full-year PAT dropped 20% to Rs 380 Cr. The company attributed the margin compression to a specific impact from a large-molecule biologics client and costs associated with operationalizing a new manufacturing facility. Additionally, a major leadership transition was announced with Siddharth Mittal appointed as the new CEO effective July 2026.
Key Highlights
Q4 FY26 revenue grew 2% YoY to Rs 1,037 Cr, while Operating EBITDA fell 12% to Rs 303 Cr.
Full-year Operating EBITDA margin contracted to 25% from 29% in the previous fiscal year.
Full-year PAT before exceptional items declined 20% YoY to Rs 380 Cr.
Board recommended a final dividend of Rs 1.25 per share for the fiscal year 2026.
Significant management change: Siddharth Mittal to succeed Peter Bains as MD and CEO from July 1, 2026.
👀 What to Watch
Investors should remain cautious as the company navigates margin pressure and slow growth linked to client-specific headwinds. Monitor the progress of the new biologics facility and the leadership transition for potential recovery signals in FY27.
Syngene Recommends Rs 1.25 Dividend; FY26 Consolidated Net Profit Drops 36% to Rs 3,167 Million
Syngene International reported a marginal 2.6% growth in consolidated revenue for FY26, reaching Rs 37,387 million. However, the company's net profit for the full year witnessed a sharp decline of 36%, falling to Rs 3,167 million from Rs 4,962 million in FY25. Despite the profit dip, the Board has recommended a final dividend of Rs 1.25 per share. The results reflect significant margin pressure, with employee benefit expenses rising to Rs 11,049 million and foreign exchange losses increasing to Rs 609 million.
Key Highlights
Recommended a final dividend of Rs 1.25 per equity share with a record date of June 26, 2026.
Consolidated FY26 revenue from operations stood at Rs 37,387 million, up from Rs 36,424 million YoY.
Full-year consolidated Net Profit declined by 36.2% to Rs 3,167 million compared to Rs 4,962 million in the previous year.
Q4 FY26 consolidated PAT was Rs 1,479 million, a decrease from Rs 1,833 million in the corresponding quarter last year.
Appointed M/s S. R. Batliboi & Associates LLP as statutory auditors for a five-year term starting from the 33rd AGM.
👀 What to Watch
Investors should exercise caution as the significant decline in profitability and flat revenue growth indicate operational headwinds. It is advisable to wait for management's guidance on margin recovery and cost-optimization strategies before increasing exposure.
Syngene Q4 FY26 Net Profit Declines 19% YoY to ₹148 Cr; ₹1.25 Dividend Declared
Syngene International reported a modest 1.8% YoY growth in consolidated revenue for Q4 FY26, reaching ₹1,036.5 crore. However, net profit for the quarter fell by 19.3% YoY to ₹147.9 crore, impacted by rising employee costs and foreign exchange volatility. For the full year FY26, the company's net profit saw a significant 36% decline to ₹316.7 crore compared to ₹496.2 crore in FY25. Despite the profit dip, the board has recommended a final dividend of ₹1.25 per share.
Key Highlights
Consolidated Q4 revenue stood at ₹1,036.5 crore, up slightly from ₹1,018 crore in the same quarter last year.
Full-year FY26 net profit dropped 36% to ₹316.7 crore from ₹496.2 crore in FY25.
Employee benefit expenses for the year increased by 12.3% to ₹1,104.9 crore.
Foreign exchange fluctuation loss for FY26 surged to ₹60.9 crore compared to a loss of ₹1.9 crore in FY25.
Board recommended a final dividend of ₹1.25 per equity share with a record date of June 26, 2026.
👀 What to Watch
Investors should exercise caution as the company is facing significant margin pressure from rising operational costs and forex losses. Monitor management's guidance on the recovery of the CDMO sector and cost-optimization strategies.
Syngene Receives ₹43.16 Crore Tax Refund Order Following Favorable Legal Rulings
Syngene International has received a favorable tax order for Assessment Year 2016-17, resulting in a sanctioned refund of ₹43.16 crore including interest. This follows a successful Writ Petition in the Karnataka High Court and a partial appeal win at the National Faceless Appeal Centre (NFAC). The order addresses a previous tax demand of ₹72.34 crore and the wrongful adjustment of refunds from earlier years. While the cash is yet to be received, the development will lead to a reduction in the company's contingent liabilities.
Key Highlights
Assessing Officer granted a refund of ₹43.16 crore, including interest, for AY 2016-17.
The order follows a Karnataka High Court ruling favoring the company regarding ₹48.91 crore in previously adjusted refunds.
The original tax demand for AY 2016-17 stood at ₹72.34 crore prior to these successful appeals.
The company expects a notable decrease in contingent liabilities related to this specific assessment year.
The refund amount is currently pending receipt but has been officially processed by the tax authorities.
👀 What to Watch
Investors should view this as a positive administrative win that strengthens the balance sheet and resolves a long-standing tax dispute. No immediate portfolio changes are necessary as the impact is non-operational.
Syngene Appoints Siddharth Mittal as MD & CEO; Kiran Mazumdar Shaw to be Executive Chairperson
Syngene International has announced a major leadership transition where Siddharth Mittal, the current MD & CEO of Biocon Limited, will take over as MD & CEO of Syngene effective July 1, 2026. This follows the resignation of Peter Bains, who will step down on June 30, 2026. Furthermore, founder Kiran Mazumdar Shaw will transition from a Non-Executive to an Executive Chairperson role for a five-year term starting April 1, 2026. These changes signal a strategic consolidation of leadership within the Biocon Group, leveraging Mittal's 20+ years of experience in complex pharma segments.
Key Highlights
Siddharth Mittal appointed as MD & CEO for a 5-year term effective July 1, 2026.
Kiran Mazumdar Shaw to become Executive Chairperson for 5 years starting April 1, 2026.
Current MD & CEO Peter Bains to resign from his position on June 30, 2026.
Incoming CEO Siddharth Mittal previously led Biocon's entry into GLP-1 therapies and generic formulations.
The leadership changes are subject to shareholder approval as per SEBI regulations.
👀 What to Watch
Investors should view this as a planned succession involving a seasoned group veteran, though the transition period warrants observation for any strategic shifts. Monitor the company's performance during the handover phase in mid-2026.
Syngene Announces Major Leadership Reshuffle; New CCO and CHRO Appointed
Syngene International has announced a significant restructuring of its senior management team, effective May 1, 2026. Three key executives, including the Interim Chief Commercial Officer, Chief Human Resources Officer, and Head of SynVent, will depart the company by mutual consent on April 30, 2026. To ensure continuity, the company has appointed Mr. Abhijit Zutshi, a Biocon veteran with over 20 years of experience, as the new CCO. Ms. Maninder Singh Puri, who has over 25 years of HR leadership experience, will join as the new CHRO.
Key Highlights
Departure of 3 senior management personnel including Interim CCO Caroline Hempstead and CHRO Andrew Webster on April 30, 2026.
Appointment of Abhijit Zutshi as CCO, leveraging his 20+ years of commercial and global generics experience at Biocon.
Appointment of Maninder Singh Puri as CHRO, bringing 25 years of experience from firms like Accenture and Biocon Generics.
Dr. Kenneth Barr, Head of SynVent and Strategic Collaborations, will also be exiting the company by mutual consent.
All leadership transitions are scheduled to be completed by May 1, 2026, to ensure organizational continuity.
👀 What to Watch
Investors should monitor the transition period for any potential disruption in commercial execution, although the appointment of experienced group veterans from Biocon is a stabilizing factor.
